News
We send the latest information from SMC Laboratories.
Redefinition from NAFLD/NASH to MASLD/MASH
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the…
STAM™ Mice Is The Best NASH model For Microbiome Therapeutics Study
We are pleased to introduce the development of drugs for non-alcoholic steatohepatitis (NASH) focusing on the …
World Hepatitis Day 2023 ~ One life, one liver ~
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help …
SMC attend Digital partnering events 【Bio Asia-Taiwan 2023】!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering&tra…
【Publication Archive】 Study focusing on iron metabolism and mitophagy for the treatment of NASH and HCC published in EMBO Rep.
Please take a look at published study focusing on intracellular iron metabolism and mitophagy as therapeutic t…
Announcement of webinar 【Chronic kidney disease model ~Instructions on how to Tubular injury score】
Today, we are excited to invite you to join our Webinar that will be taking place on July 20th (JST) from 9:30…
Webinar Archive
I am writing you today to share with you about our Webinar. We occasionally organize webinars focusing on NASH…
89bio Inc. and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s 89bio Inc. (CA/ISR)will present results of a study using STAM™ mic…
AprilBio Co., Ltd., and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s AprilBio Co., Ltd., (KOR) will present results of a study using STAM&tra…
Our article was published in Nature Brand magazine (Biopharma Dealmakers)!
It's about the concept of metabolic-associated fatty liver disease (MAFLD) and how we work with it, which…